FDA Clears Takeda’s First-in-Class Oral Therapy for Narcolepsy Type 1
The U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s oral medication for narcolepsy type 1, marking the first approved therapy to directly address the orexin deficiency that underlies the disorder. The decision relied on clinical trials showing daytime wakefulness improvements versus placebo. Final U.S. patient access will dep…